Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Palovarotene (Primary)
  • Indications Bone cancer
  • Focus Therapeutic Use
  • Acronyms MO-Ped
  • Sponsors Clementia Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2018 According to a Clementia Pharmaceuticals media release,Over the next 12 months company expect to complete enrollment in this trial.
    • 09 Aug 2018 According to a Clementia Pharmaceuticals media release, the first patient has been enrolled in the trial in April 2018.
    • 20 Apr 2018 According to a Clementia Pharmaceuticals media release, 12-month interim data readout is anticipated in the first half of 2020, with 24-month top-line results in the first half of 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top